Theodore A Martinot

List of Publications by Year
in descending order

17	570	840776 11	839539 18
papers	citations	h-index	g-index

22	22	22	653
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Total Synthesis and Biological Evaluation of Amaryllidaceae Alkaloids:â€‰ Narciclasine, ent-7-Deoxypancratistatin, Regioisomer of 7-Deoxypancratistatin, 10b-epi-Deoxypancratistatin, and Truncated Derivatives1. Journal of Organic Chemistry, 2002, 67, 8726-8743.	3.2	182
2	A short chemoenzymatic synthesis of (+)-narciclasine. Tetrahedron Letters, 1999, 40, 3077-3080.	1.4	84
3	Synthesis, Structure, and Biological Evaluation of Novel N- and O-Linked Diinositols. Journal of the American Chemical Society, 2002, 124, 10416-10426.	13.7	57
4	Artificial Genetic Systems:â€‰ Exploiting the â€œAromaticityâ€•Formalism To Improve the Tautomeric Ratio for Isoguanosine Derivatives. Journal of Organic Chemistry, 2004, 69, 3972-3975.	3.2	42
5	Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy. ACS Medicinal Chemistry Letters, 2019, 10, 1530-1536.	2.8	38
6	Synthesis of the Bis-tetrahydropyran Core of Amphidinol 3. Organic Letters, 2010, 12, 3890-3893.	4.6	32
7	Data-Rich Experimentation Enables Palladium-Catalyzed Couplings of Piperidines and Five-Membered (Hetero)aromatic Electrophiles. Organic Process Research and Development, 2019, 23, 1725-1739.	2.7	24
8	Novel O- and N-Linked Inositol Oligomers: A New Class of Unnatural Saccharide Mimics. Synthesis, 2001, 2001, 0952-0956.	2.3	22
9	Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy. ACS Medicinal Chemistry Letters, 2020, 11, 582-588.	2.8	18
10	Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 389-396.	2.8	14
11	Development of a Manufacturing Process for an HCV Protease Inhibitor Candidate Molecule. Organic Process Research and Development, 2015, 19, 270-283.	2.7	12
12	A Design of Experiments Approach to a Robust Final Deprotection and Reactive Crystallization of IPI-926, A Novel Hedgehog Pathway Inhibitor. Organic Process Research and Development, 2015, 19, 1693-1702.	2.7	9
13	Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 1678-1688.	2.8	9
14	Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing. Journal of Medicinal Chemistry, 2022, 65, 6001-6016.	6.4	8
15	Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 1435-1440.	2.8	7
16	Development of a Zinc-Mediated Approach to a 2,3-cis-Pyrrolidine Arginase Inhibitor. Organic Process Research and Development, 2020, 24, 1457-1466.	2.7	6
17	Process Safety Considerations for the Supply of a High-Energy Oxadiazole IDO1-Selective Inhibitor. Organic Process Research and Development, 2019, 23, 1178-1190.	2.7	4